Treatment delay and facility case volume are associated with survival in early-stage glottic cancer

Laryngoscope

Volumn 127, Issue 3, 2017, Pages 616-622

  Cheraghlou, Shayan ^a   Kuo, Phoebe ^a   Judson, Benjamin L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

facility case volume; Glottic cancer; NCDB; survival; treatment delay

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EARLY CANCER; FEMALE; HUMAN; KAPLAN MEIER METHOD; LARYNX SQUAMOUS CELL CARCINOMA; LARYNX SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY DELAY; ADJUVANT RADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; DISEASE FREE SURVIVAL; EARLY CANCER DIAGNOSIS; GLOTTIS; HIGH VOLUME HOSPITAL; HOSPITAL ADMISSION; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURGERY; SURVIVAL ANALYSIS; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GLOTTIS; HOSPITALS, HIGH-VOLUME; HUMANS; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; ORGAN SPARING TREATMENTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; WAITING LISTS;

EID: 84994252289     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.26259     Document Type: Article

References (44)

1. American Cancer Society. What are the key statistics about laryngeal and hypopharyngeal cancers? Available at: http://www.cancer.org/cancer/laryngealandhypopharyngealcancer/detailedguide/laryngeal-and-hypopharyngeal-cancer-key-statistics. Accessed February 15, 2016.
2. Dechaphunkul T. Epidemiology, risk factors, and overall survival rate of laryngeal cancer in Songklanagarind Hospital. J Med Assoc Thai 2011;94:355–360.
3. Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 2008;41:673–695.
4. Tachibana T, Orita Y, Marunaka H, et al. Glottic cancer in patients without complaints of hoarseness. Head Neck 2016;38(suppl 1):E316–E320. doi: 10.1002/hed.23992.
5. Raitiola H, Pukander J, Laippala P. Glottic and supraglottic laryngeal carcinoma: differences in epidemiology, clinical characteristics and prognosis. Acta Otolaryngol 1999;119:847–851.
6. American Cancer Society. Survival rates for laryngeal and hypopharyngeal cancers by stage. Available at: http://www.cancer.org/cancer/laryngealandhypopharyngealcancer/detailedguide/laryngeal-and-hypopharyngeal-cancer-survival-rates. Accessed February 15, 2016.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers (Version I.2015). Available at: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed February 15, 2016.
8. Bryce DP, Ireland PE, Rider WD. Experience in the surgical and radiological treatment in 500 cases of carcinoma of the larynx. Laryngoscope 1963;73:1383–1385.
9. Cohen SM, Garrett CG, Dupont WD, Ossoff RH, Courey MS. Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. Ann Otol Rhinol Laryngol 2006;115:581–586.
10. Smith JC, Johnson JT, Cognetti DM, et al. Quality of life, functional outcome, and costs of early glottic cancer. Laryngoscope 2003;113:68–76.
11. Back G, Sood S. The management of early laryngeal cancer: options for patients and therapists. Curr Opin Otolaryngol Head Neck Surg 2005;13:85–91.
12. Groome PA, O'Sullivan B, Irish JC, et al. Glottic cancer in Ontario, Canada and the SEER areas of the United States. Do different management philosophies produce different outcome profiles? J Clin Epidemiol 2001;54:301–315.
13. Hinerman RW, Mendenhall WM, Amdur RJ, Villaret DB, Robbins KT. Early laryngeal cancer. Curr Treat Options Oncol 2002;3:3–9.
14. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1–T2 glottic carcinomas. Cancer 2004;100:1786–1792.
15. Warner L, Chudasama J, Kelly CG, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev 2014;12:CD002027. doi: 10.1002/14651858.CD002027.pub2.
16. Yoo J, Lacchetti C, Hammond JA, Gilbert RW. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer: a systematic review. Head Neck 2014;36:1807–1819.
17. Kirchner JA, Owen JR. Five hundred cancers of the larynx and pyriform sinus. Results of treatment by radiation and surgery. Laryngoscope 1977;87:1288–1303.
18. Thurnher D, Erovic B, Frommlet F, et al. Challenging a dogma–surgery yields superior long-term results for T1a squamous cell carcinoma of the glottic larynx compared to radiotherapy. Eur J Surg Oncol 2008;34:692–698.
19. Misono S, Marmor S, Yueh B, Virnig BA. T1 glottic carcinoma: do comorbidities, facility characteristics, and sociodemographics explain survival differences across treatment? Otolaryngol Head Neck Surg 2015;152:856–862.
20. Li P, Hu W, Zhu Y, Liu J. Treatment and predictive factors in patients with recurrent laryngeal carcinoma: a retrospective study. Oncol Lett 2015;10:3145–3152.
21. Misono S, Marmor S, Yueh B, Virnig BA. Treatment and survival in 10,429 patients with localized laryngeal cancer: a population-based analysis. Cancer 2014;120:1810–1817.
22. Jones A, Beasley N, Houghton D, Husband D. The effects of age on survival and other parameters in squamous cell carcinoma of the oral cavity, pharynx and larynx. Clin Otolaryngol Allied Sci 1998;23:51–56.
23. Shin JY, Truong MT. Racial disparities in laryngeal cancer treatment and outcome: a population-based analysis of 24,069 patients. Laryngoscope 2015;125:1667–1674.
24. Mehta V, Shi Z, Mills GM, Nathan CA, Shi R. Effect of payer status on relative survival of patients with laryngeal cancer. Anticancer Res 2016;36:327–333.
25. Eiband JD, Elias EG, Suter CM, Gray WC, Didolkar MS. Prognostic factors in squamous cell carcinoma of the larynx. Am J Surg 1989;158:314–317.
26. Vendelbo Johansen L, Overgaard J, Hjelm-Hansen M, Gadeberg CC. Primary radiotherapy of T1 squamous cell carcinoma of the larynx: analysis of 478 patients treated from 1963 to 1985. Int J Radiat Oncol Biol Phys 1990;18:1307–1313.
27. Warde P, O'Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347–353.
28. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Ann Oncol 2003;14:v61–v118.
29. Sabin SL, Rosenfeld RM, Sundaram K, Har-El G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J 1999;78:578.
30. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer 2001;92:2109–2116.
31. Chen AY, Matson LK, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal cancer. Head Neck 2001;23:566–572.
32. Burke LS, Greven KM, McGuirt WT, Case D, Hoen HM, Raben M. Definitive radiotherapy for early glottic carcinoma: prognostic factors and implications for treatment. Int J Radiat Oncol Biol Phys 1997;38:1001–1006.
33. Motta G, Esposito E, Motta S, Tartaro G, Testa D. CO2 laser surgery in the treatment of glottic cancer. Head Neck 2005;27:566–574.
34. Marshak G, Brenner B, Shvero J, et al. Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys 1999;43:1009–1013.
35. Mantravadi RV, Liebner EJ, Haas RE, Skolnik EM, Applebaum EL. Cancer of the glottis: prognostic factors in radiation therapy. Radiology 1983;149:311–314.
36. Bennett SH, Futrell JW, Roth JA, Hoye RC, Ketcham AS. Prognostic significance of histologic host response in cancer of the larynx or hypopharynx. Cancer 1971;28:1255–1265.
37. Welkoborsky H-J, Dienes H-P, Hinni M, Mann WJ. Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers. Ann Otol Rhinol Laryngol 1995;104:503–510.
38. Ranelletti FO, Almadori G, Rocca B, et al. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 2001;95:343–349.
39. Chen AY, Pavluck A, Halpern M, Ward E. Impact of treating facilities' volume on survival for early-stage laryngeal cancer. Head Neck 2009;31:1137–1143.
40. Barton MB, Morgan G, Smee R, Tiver KW, Hamilton C, Gebski V. Does waiting time affect the outcome of larynx cancer treated by radiotherapy? Radiother Oncol 1997;44:137–141.
41. Fortin A, Bairati I, Albert M, Moore L, Allard J, Couture C. Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:929–936.
42. Brouha XD, Op De Coul B, Terhaard CH, Hordijk GJ. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma? Clin Otolaryngol Allied Sci 2000;25:215–218.
43. Hansen O, Larsen S, Bastholt L, Godballe C, Jorgensen KE. Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients. Int J Radiat Oncol Biol Phys 2005;61:789–794.
44. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999;341:1359–1367.